文献速递心脑血管急症

急性冠脉综合征合并多支冠脉病变患者立即完全血运重建与分期完全血运重建的比较(BIOVASC):一项前瞻性、开放标签、非劣效性随机试验

Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial.
PubMed 文献 · Lancet · 2023-03-05
一句话结论在急性冠脉综合征合并多支冠脉病变患者中,立即完全血运重建在1年主要复合终点上非劣于分期完全血运重建,并降低了心肌梗死和计划外缺血驱动的血运重建。

BIOVASC试验在比利时、意大利、荷兰和西班牙的29家医院纳入764例立即完全血运重建和761例分期完全血运重建的急性冠脉综合征合并多支冠脉病变患者,随机1:1分组。主要终点为1年全因死亡、心肌梗死、任何计划外缺血驱动的血运重建或脑血管事件的复合终点,立即组发生57例(7.6%),分期组71例(9.4%)(HR 0.78,95%CI 0.55-1.11,p非劣效=0.0011),达到非劣效界值(HR 95%CI上限不超过1.39)。心肌梗死立即组14例(1.9%)vs分期组34例(4.5%)(HR 0.41,95%CI 0.22-0.76,p=0.0045),计划外缺血驱动的血运重建立即组31例(4.2%)vs分期组50例(6.7%)(HR 0.61,95%CI 0.39-0.95,p=0.030),全因死亡两组无差异(14例[1.9%] vs 9例[1.2%];HR 1.56,95%CI 0.68-3.61,p=0.30)。

要点

  • 在急性冠脉综合征合并多支冠脉病变患者中,立即完全血运重建在1年主要复合终点上非劣于分期完全血运重建(HR 0.78,95%CI 0.55-1.11,p非劣效=0.0011)。
  • 立即完全血运重建组心肌梗死发生率低于分期组(1.9% vs 4.5%;HR 0.41,95%CI 0.22-0.76,p=0.0045)。
  • 立即完全血运重建组计划外缺血驱动的血运重建少于分期组(4.2% vs 6.7%;HR 0.61,95%CI 0.39-0.95,p=0.030)。
  • 两组全因死亡无差异(1.9% vs 1.2%;HR 1.56,95%CI 0.68-3.61,p=0.30)。
  • 非劣效性界值为主要终点HR的95%CI上限不超过1.39。

适用人群与场景

  • 年龄18-85岁,表现为ST段抬高型心肌梗死或非ST段抬高型急性冠脉综合征,合并多支冠状动脉病变(至少两支直径≥2.5 mm且目测狭窄≥70%或冠状动脉生理学测试阳性),且有明确可识别的罪犯病变。
  • 研究在比利时、意大利、荷兰和西班牙的29家医院进行。

诊断标准与关键阈值

  • 多支冠状动脉病变定义:两支或以上冠状动脉直径≥2.5 mm且目测狭窄≥70%或冠状动脉生理学测试阳性。
  • 非劣效性界值:主要终点风险比(HR)的95%CI上限不超过1.39。

处置流程与药物剂量

  • 立即完全血运重建:在本次手术中首先处理罪犯病变,随后由术者判断对其它临床显著的非罪犯病变行PCI。
  • 分期完全血运重建:本次手术仅处理罪犯病变,在本次手术后6周内对术者判断的所有临床显著非罪犯病变行PCI。

研究设计与关键结果

  • 研究类型:前瞻性、开放标签、非劣效性随机试验,在比利时、意大利、荷兰和西班牙的29家医院进行。
  • 样本量:764例随机分配至立即完全血运重建组,761例随机分配至分期完全血运重建组,均纳入意向性治疗分析。
  • 人群特征:立即组中位年龄65.7岁(IQR 57.2-72.9),男性598例(78.3%);分期组中位年龄65.3岁(IQR 58.6-72.9),男性589例(77.4%)。
  • 主要终点(1年全因死亡、心肌梗死、任何计划外缺血驱动的血运重建或脑血管事件的复合终点):立即组57例(7.6%),分期组71例(9.4%)(HR 0.78,95%CI 0.55-1.11,p非劣效=0.0011)。
  • 全因死亡:立即组14例(1.9%),分期组9例(1.2%)(HR 1.56,95%CI 0.68-3.61,p=0.30)。
  • 心肌梗死:立即组14例(1.9%),分期组34例(4.5%)(HR 0.41,95%CI 0.22-0.76,p=0.0045)。
  • 计划外缺血驱动的血运重建:立即组31例(4.2%),分期组50例(6.7%)(HR 0.61,95%CI 0.39-0.95,p=0.030)。

证据类型、等级与局限

  • 证据类型:前瞻性、开放标签、非劣效性随机试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在急性冠脉综合征合并多支冠脉病变患者中,立即完全血运重建在主要复合终点上非劣于分期完全血运重建,并可能与心肌梗死和计划外缺血驱动的血运重建减少相关。

指南或共识出处

  • BIOVASC试验,注册号ClinicalTrials.gov NCT03621501。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In patients with acute coronary syndrome and multivessel coronary disease, complete revascularisation by percutaneous coronary intervention (PCI) is associated with improved clinical outcomes. We aimed to investigate whether PCI for non-culprit lesions should be attempted during the index procedure or staged.

METHODS: This prospective, open-label, non-inferiority, randomised trial was done at 29 hospitals across Belgium, Italy, the Netherlands, and Spain. We included patients aged 18-85 years presenting with ST-segment elevation myocardial infarction or non-ST-segment elevation acute coronary syndrome and multivessel (ie, two or more coronary arteries with a diameter of 2·5 mm or more and ≥70% stenosis based on visual estimation or positive coronary physiology testing) coronary artery disease with a clearly identifiable culprit lesion. A web-based randomisation module was used to randomly assign patients (1:1), with a random block size of four to eight, stratified by study centre, to undergo immediate complete revascularisation (PCI of the culprit lesion first, followed by other non-culprit lesions deemed to be clinically significant by the operator during the index procedure) or staged complete revascularisation (PCI of only the culprit lesion during the index procedure and PCI of all non-culprit lesions deemed to be clinically significant by the operator within 6 weeks after the index procedure). The primary outcome was the composite of all-cause mortality, myocardial infarction, any unplanned ischaemia-driven revascularisation, or cerebrovascular events at 1 year after the index procedure. Secondary outcomes included all-cause mortality, myocardial infarction, and unplanned ischaemia-driven revascularisation at 1 year after the index procedure. Primary and secondary outcomes were assessed in all randomly assigned patients by intention to treat. Non-inferiority of immediate to staged complete revascularisation was considered to be met if the upper boundary of the 95% CI of the hazard ratio (HR) for the primary outcome did not exceed 1·39. This trial is registered with ClinicalTrials.gov, NCT03621501.

FINDINGS: Between June 26, 2018, and Oct 21, 2021, 764 patients (median age 65·7 years [IQR 57·2-72·9] and 598 [78·3%] males) were randomly assigned to the immediate complete revascularisation group and 761 patients (median age 65·3 years [58·6-72·9] and 589 [77·4%] males) were randomly assigned to the staged complete revascularisation group, and were included in the intention-to-treat population. The primary outcome at 1 year occurred in 57 (7·6%) of 764 patients in the immediate complete revascularisation group and in 71 (9·4%) of 761 patients in the staged complete revascularisation group (HR 0·78, 95% CI 0·55-1·11, pnon-inferiority=0·0011). There was no difference in all-cause death between the immediate and staged complete revascularisation groups (14 [1·9%] vs nine [1·2%]; HR 1·56, 95% CI 0·68-3·61, p=0·30). Myocardial infarction occurred in 14 (1·9%) patients in the immediate complete revascularisation group and in 34 (4·5%) patients in the staged complete revascularisation group (HR 0·41, 95% CI 0·22-0·76, p=0·0045). More unplanned ischaemia-driven revascularisations were performed in the staged complete revascularisation group than in the immediate complete revascularisation group (50 [6·7%] patients vs 31 [4·2%] patients; HR 0·61, 95% CI 0·39-0·95, p=0·030).

INTERPRETATION: In patients presenting with acute coronary syndrome and multivessel disease, immediate complete revascularisation was non-inferior to staged complete revascularisation for the primary composite outcome and was associated with a reduction in myocardial infarction and unplanned ischaemia-driven revascularisation.

FUNDING: Erasmus University Medical Center and Biotronik.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Diletti R, den Dekker WK, Bennett J, et al. Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial. Lancet. 2023. PMID: 36889333. doi:10.1016/S0140-6736(23)00351-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。